{
    "clinical_study": {
        "@rank": "166345", 
        "acronym": "IPS-II", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Targeted Lung Denervation Therapy (TLD Therapy)"
        }, 
        "brief_summary": {
            "textblock": "Targeted Lung Denervation (TLD) Therapy will be a safe method to ablate the airway nerve\n      trunks that travel parallel to and outside of the main bronchi and into the lungs to achieve\n      targeted lung denervation and potentially improve breathing and quality of life for patients\n      suffering from COPD.\n\n      Use of the IPS System will be technically feasible in accessing the target treatment\n      location and delivering RF energy to the target treatment location."
        }, 
        "brief_title": "Evaluation of the IPS System for TLD Therapy in Patients With COPD", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  FEV1 30% to 60%\n\n          -  Patient is diagnosed with COPD\n\n          -  Positive relative change in FEV1 of greater than 15%\n\n          -  Patient 40 years of age or older at the time of consent\n\n          -  Smoking history of at least 10 pack years\n\n          -  Non-smoking for a minimum of 6 months prior to consent and agrees to continue not\n             smoking for the duration of the study\n\n        Exclusion Criteria:\n\n          -  Documented history or current evidence of pulmonary hypertension Documented history\n             or current evidence of polycythemia level of greater\n\n          -  Documented history or current evidence of congestive heart failure\n\n          -  Patient has an SaO2 less than or equal to 88% or a PaO2 less than or equal to 7.3 kPa\n             (55 mm Hg) on room air\n\n          -  Patient has a PaCO2 > 8.0 kPa (60 mm Hg)\n\n          -  Prior lung transplant, LVRS, LVR, median sternotomy, bullectomy or lobectomy\n\n          -  Pulmonary nodule requiring surgery\n\n          -  History of recurrent respiratory infections (more than 3 hospitalizations within 1\n             year of enrollment)\n\n          -  Presence of a pacemaker, internal defibrillator or other implantable electronic\n             devices j. Active respiratory infection within the past 4 weeks k. COPD exacerbation\n             within the past 4 weeks l. Myocardial infarction (MI) within the last 6 months m.\n             Unstable or life threatening arrhythmia within the last year n. Malignancy treated\n             with radiation or chemotherapy within the last 2 years o. Documented history of other\n             respiratory diseases (cystic fibrosis, tuberculosis, vocal chord dysfunction,\n             Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716598", 
            "org_study_id": "CLP-002", 
            "secondary_id": "CVI-12-03-005102"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "TLD Therapy will be achieved bronchoscopically.", 
            "intervention_name": "IPS System", 
            "intervention_type": "Device", 
            "other_name": [
                "TLD Therapy", 
                "Targeted Lung Denervation Therapy"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "COPD", 
            "TLD Therapy", 
            "Targeted Lung Denervation Therapy", 
            "IPS", 
            "Innovative Pulmonary Solutions, Inc.", 
            "Holaira, Inc."
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sanatoriumstrasse 2", 
                        "country": "Austria", 
                        "state": "Vienna", 
                        "zip": "1140"
                    }, 
                    "name": "Otto-Wagner Hospital and Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier et Universitaire de Grenoble"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier University de Reims"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "Nouvel Hopital Civil"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "IPS-II Study: Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) - A Pilot Study.", 
        "overall_official": {
            "affiliation": "Otto-Wagner Hospital, Vienna, Austria", 
            "last_name": "Arschang Valipour, MD, FCCP, Ass. Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Dutch Health Care Inspectorate", 
                "France: ANMS", 
                "Austria: BASG/AGES"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be evaluated as freedom from documented and sustained worsening of COPD directly attributable to the investigational device or procedure.", 
            "measure": "Primary Safety Endpoint", 
            "safety_issue": "Yes", 
            "time_frame": "365 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Performance will be evaluated as the ability of the IPS System to access the target treatment area and deliver RF energy to the target treatment site at the time of the procedure, as well as confirmation of clinical evidence of successful lung denervation.", 
            "measure": "Performance", 
            "safety_issue": "No", 
            "time_frame": "365 days"
        }, 
        "source": "Holaira", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Holaira", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}